Human leucocyte antigen genotype association with the development of immune-related adverse events in patients with non-small cell lung cancer treated with single agent immunotherapy
-
Published:2022-09
Issue:
Volume:172
Page:98-106
-
ISSN:0959-8049
-
Container-title:European Journal of Cancer
-
language:en
-
Short-container-title:European Journal of Cancer
Author:
Abed AfafORCID,
Law Ngie,
Calapre Leslie,
Lo JohnnyORCID,
Bhat Vikas,
Bowyer Samantha,
Millward Michael,
Gray Elin S.ORCID
Subject
Cancer Research,Oncology
Reference40 articles.
1. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer;Borghaei;N Engl J Med,2015
2. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer;Brahmer;N Engl J Med,2015
3. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial;Mok;Lancet,2019
4. A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors;Arnaud-Coffin;Int J Cancer,2019
5. Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors;Choi;Immune Netw,2020
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献